Gallbladder cancer (GBC) is an uncommon disease in the majority of the world despite
being the most common and aggressive malignancy of the biliary tree. Early diagnosis is …

Gallbladder cancer (GBC) represents the most common and aggressive type among the
biliary tree cancers (BTCs). Complete surgical resection offers the only chance for cure; …

Background: A British randomised study of gemcitabine plus cisplatin (GC) combination
showed promising results in biliary tract cancer (BTC) patients. In our study, we evaluated …

Background The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report
examines the patterns of presentation, adjuvant treatment and survival of a large cohort of …

Hepatobiliary cancers are highly lethal. In 2008, approximately 21,370 persons in the United
States were estimated to be diagnosed with liver or intrahepatic bile duct cancer and 9520 …

Purpose We designed this study to evaluate efficacy of modified gemcitabine and oxaliplatin
(mGEMOX) over best supportive care (BSC) or fluorouracil (FU) and folinic acid (FA) in …

Purpose Biliary cancer has a poor prognosis, and chemotherapy has had little impact. The
objectives of this trial were to determine the response rate, time to disease progression …

Aim: Gallbladder cancer is the fifth most common cancer involving the gastrointestinal tract,
but it is the most common malignant tumour of the biliary tract worldwide. The percentage of …

BACKGROUND. The objective of this report was to present data from an open‐label cohort
study in which patients with intrahepatic cholangiocarcinoma (ICC) underwent …

Immune checkpoint blockade (ICB) therapies have had a tremendous impact on cancer
therapy. However, most patients harbor a poorly immunogenic tumor microenvironment …